

Myobloc® (rimabotulinumtoxinB)

When requesting Myobloc® (rimabotulinumtoxinB), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines for the covered indications.

FDA-approved Indication

Myobloc (rimabotulinumtoxinB) is indicated for the treatment of adults with cervical dystonia.

Coverage Guidelines

The individual must meet **all** of the following criteria for cervical dystonia:

- Has failed or developed a tolerance to Botox® (onabotulinumtoxinA); AND
- Is 18 years of age or older.

Approval duration: 12 months

Recommended Dosing

Cervical Dystonia

Approve up to a maximum dose of 5000 units, administered intramuscularly not more frequently than once every 12 weeks.

References

1. Myobloc® (rimabotulinumtoxinB) [prescribing information]. South San Francisco, CA: Solstice Neurosciences, Inc.: May 2010. Accessed July 1, 2019.
2. Myobloc® (rimabotulinumtoxinB). Ln: DRUGDEX System Micromedex. Greenwood Village, CO: Thompson Reuters (Healthcare) Inc. [Updated November 17, 2017; Accessed July 1, 2019]
3. Simpson, DN et al. Practice guideline update summary. Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Report of the Guideline Development Subcommittee of the American Academy of Neurology, Neurology. 2016; 86(19):1818-1826.